The revenue pre-announcement is clearly positive and likely to drive the stock higher on the session. However, the abrupt CFO departure after only 3 months introduces execution risk and may cap upside. Traders should watch for the full Q2 earnings report on August 4 for EPS, margins, and pipeline updates. The interim CFO appointment provides continuity but a permanent CFO search is underway.
Price Chart
Executive Summary
Harmony Biosciences pre-announced record Q2 2026 WAKIX net product revenue of ~$261M (+30% YoY), reaffirmed full-year guidance of $1.0B-$1.04B, and disclosed the immediate departure of CFO Glenn Reicin (hired only ~3 months ago) with the controller appointed as interim CFO. The revenue beat is strongly positive, but the abrupt CFO departure introduces governance uncertainty that partially offsets the bullish signal.
Key Financial Metrics
Key Facts
- Q2 2026 preliminary WAKIX net product revenue of ~$261M, a record quarter, representing 30% YoY growth and 21% sequential growth over Q1 2026
- Reaffirmed full-year 2026 net product revenue guidance of $1.0B to $1.04B
- CFO Glenn Reicin stepped down effective July 16, 2026 to pursue other opportunities; employed only since April 14, 2026 (~3 months)
- Stephen Mollichella, SVP & Controller, appointed Interim Principal Financial Officer
- Full Q2 2026 financial results to be reported on August 4, 2026
- Separation agreement provides Reicin $500K severance over 12 months plus $62,500 lump sum and benefits
- Company states departure is not due to any disagreement with operations, policies, or practices
Financial Impact
Q2 2026 revenue of ~$261M vs consensus estimate of $242.1M represents a ~7.8% beat; 30% YoY growth significantly above the 17% growth rate reported in Q1 2026
Risk Factors
- CFO departure after only 3 months raises questions about internal stability and may signal undisclosed issues
- Preliminary revenue only — full P&L with EPS, margins, and cash flow details not yet available
- Guidance maintained but not raised despite strong Q2 beat, suggesting management sees potential headwinds in H2
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-084095 |
| Document: hrmy-20260716x8k.htm | 0001104659-26-084095 |
| Document: hrmy-20260716xex99d1.htm | 0001104659-26-084095 |
| Document: 0001104659-26-084095-index-headers.html | 0001104659-26-084095 |
| Document: 0001104659-26-084095-index.html | 0001104659-26-084095 |
| Document: 0001104659-26-084095.txt | 0001104659-26-084095 |
| 8-K Data (Synthetic) | 0001104659-26-084095 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $38.78 $39.52 | ▲ +1.91% | ▲ +2.01% | $40.53 (+4.53%) |
Aug 4, 2026 8w ago | Press Release | $38.78 $39.52 | ▲ +1.91% | ▲ +2.01% | $40.53 (+4.53%) |
Jul 16, 2026 11w ago | 8-K | $33.53 $35.80 | ▲ +6.77% | ▲ +8.44% | $40.53 (+20.89%) |
Jun 30, 2026 13w ago | 144 | $36.00 $38.26 | ▼ −6.28% | ▼ −6.02% | $40.53 (−12.60%) |
Jun 24, 2026 14w ago | 144 | $34.13 $36.00 | ▼ −5.48% | ▼ −3.92% | $40.53 (−18.77%) |
Jun 9, 2026 16w ago | 144 | $35.48 $33.83 | ▼ −4.65% | ▼ −8.08% | $40.53 (+14.25%) |
Jun 5, 2026 16w ago | 144 | $32.39 $34.18 | ▲ +5.53% | ▲ +3.41% | $40.53 (+25.15%) |
May 19, 2026 19w ago | 3 | $30.44 $30.76 | ▲ +1.05% | ▼ −1.25% | $40.53 (+33.16%) |
May 7, 2026 21w ago | 8-K | $31.42 $30.83 | ▼ −1.88% | ▼ −3.38% | $40.53 (+29.01%) |
Apr 14, 2026 24w ago | 8-K | $29.29 $32.14 | ▲ +9.73% | ▲ +8.34% | $40.53 (+38.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access